60 Degrees Pharmaceuticals to Present at H.C. Wainwright Conference — 60 Degrees Pharmaceuticals, Inc.

Event summary

60 Degrees Pharmaceuticals will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
A pre-recorded presentation will be available on-demand starting September 11, 2026, at 7:00 a.m. ET.
Management will be available for one-on-one investor meetings during the conference.
The company focuses on developing medicines for vector-borne diseases, with ARAKODA® approved for malaria prevention in 2018.
60 Degrees Pharmaceuticals has 3 active clinical trials underway for babesiosis.

The big picture

60 Degrees Pharmaceuticals' participation in the H.C. Wainwright conference underscores its efforts to engage with investors and highlight its focus on vector-borne diseases. The company's strategic emphasis on expanding its clinical trials and securing regulatory approvals aligns with the growing global concern over emerging infectious diseases. The success of its investor outreach could influence its ability to secure necessary funding for further development and commercialization.

What we're watching

Clinical Trial Progress: The pace at which 60 Degrees Pharmaceuticals advances its clinical trials for babesiosis will determine its pipeline strength and investor confidence.
Investor Sentiment: How the company's presentation and one-on-one meetings impact investor perception and potential funding or partnerships.
Regulatory Approvals: Whether the company can secure additional FDA approvals for non-malaria indications of tafenoquine to expand its market reach.